Interleukin 11, Recombinant, Human (IL-11)

Recombinant Human IL-11 is a single, non-glycosylated polypeptide chain containing 179 amino acids and having a molecular mass of 19256.29 Dalton.\n\nEndotoxin:\n(same/less than) 0.1ng/ug (IEU/ug) of rHuIL-11\n\nBiological Activity:\nrHuIL-11 is fully biologically active when compared to standard. The ED50 as determined by the dose-dependent stimulation of the proliferation of murine 7TD1 was found to be < 10ng/ml, corresponding to a Specific Activity of 1x10e5 IU/mg.\n\nAA Seqeunce:\nThe sequence of the first five N-terminal amino acids was determined and was found to be Gly-Pro-Pro-Pro-Gly. N-terminal methionine has been completely removed enzymatically. \n\nDimers and Aggregates:\n(same/less than) 1% as determined by silver-stained SDS-PAGE gel analysis.\n\nProtein Content:\nProtein quantitation was carried out by two independent methods: \n1. UV spectroscopy at 280nm using the absorbency value of 0.95 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). \n2. Analysis by RP-HPLC, using a calibrated solution of IL-11 as a Reference Standard.\n\nStorage and Stability:\nLyophilized powder may be stored at 4 degrees C for short-term only. Reconstitute to nominal volume by adding sterile dH2O and store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

I8433-01

Size

2ug

Form

Supplied as a lyophilized powder. No additives. Reconstitute in sterile ddH2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.

Purity

(same/more than) 98% by RP-HPLC, anion-exchange FPLC, reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified.Endotoxin: (same/less than) 0.1ng/ug (IEU/ug)

References

1. Effects of recombinant human interleukin 11 on thrombocytopenia and neutropenia in irradiated rhesus monkeys. Hao J, Sun L, Xiong G, Dong B, Radiat Res 2004 Aug;162(2):157-63 2. A multiple-dose, safety, tolerability, pharmacokinetics and pharmacodynamic study of oral recombinant human interleukin-11 (oprelvekin). Cotreau MM, Stonis L, Schwertschlag US, Biopharm Drug Dispos 2004 Oct;25(7):291-6 3. Optimizing storage stability of lyophilized recombinant human interleukin-11 with disaccharide/hydroxyethyl starch mixtures. Garzon-Rodriguez W, Koval RL, Krishnan S, J Pharm Sci 2004 Mar;93(3):684-96 4. Oral treatment with recombinant human interleukin-11 improves mucosal transport in the colon of human leukocyte antigen-B27 transgenic rats. Venkova K, Keith JC Jr, J Pharmacol Exp Ther 2004 Jan;308(1):206-13 5. Characterization of a potent human interleukin-11 agonist. Harmegnies D, Wang XM, Leon A, Goormaghtigh E, Biochem J 2003 Oct 1;375(Pt 1):23-32 6. [Expression and purification of recombinant human interleukin-11 in Pichia pastoris] Zhu JK, Xu ZX, Ming TS, Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2001 Apr;23(2):127-31.